Published: 17 August 2015
Author(s): Antoine Froissart, Agnès Veyradier, Miguel Hié, Ygal Benhamou, Paul Coppo, French Reference Center for Thrombotic Microangiopathies

Despite a significant improvement of thrombotic thrombocytopenic purpura (TTP) prognosis since the use of plasma exchange, morbidity and mortality remained significant because of poor response to standard treatment or exacerbations and relapses. Rituximab, a chimeric monoclonal antibody directed against the B-lymphocyte CD20 antigen, has shown a particular interest in this indication. Recent studies also reported strong evidence for its efficiency in the prevention of relapses. This review addresses these recent progresses and still opened questions in this topic: should rituximab be proposed in all patients at the acute phase? Should all patients benefit from a preemptive treatment? Is the infectious risk acceptable in this context?


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.